Compare COMBAT DRUGS with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DECIPHER LABS vs AUROBINDO PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DECIPHER LABS AUROBINDO PHARMA DECIPHER LABS/
AUROBINDO PHARMA
 
P/E (TTM) x 4.6 11.2 41.1% View Chart
P/BV x 3.8 1.5 257.7% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 DECIPHER LABS   AUROBINDO PHARMA
EQUITY SHARE DATA
    DECIPHER LABS
Mar-21
AUROBINDO PHARMA
Mar-21
DECIPHER LABS/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs411,023 4.0%   
Low Rs18333 5.4%   
Sales per share (Unadj.) Rs55.0422.8 13.0%  
Earnings per share (Unadj.) Rs1.492.0 1.5%  
Cash flow per share (Unadj.) Rs2.2110.0 2.0%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Avg Dividend yield %00.6 0.0%  
Book value per share (Unadj.) Rs13.6374.3 3.6%  
Shares outstanding (eoy) m10.10585.94 1.7%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.51.6 33.5%   
Avg P/E ratio x21.37.4 288.6%  
P/CF ratio (eoy) x13.46.2 217.8%  
Price / Book Value ratio x2.21.8 120.3%  
Dividend payout %04.3 0.0%   
Avg Mkt Cap Rs m298397,398 0.1%   
No. of employees `000NANA-   
Total wages/salary Rs m47335,350 1.3%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m556247,746 0.2%  
Other income Rs m63,809 0.2%   
Total revenues Rs m562251,555 0.2%   
Gross profit Rs m3581,480 0.0%  
Depreciation Rs m810,554 0.1%   
Interest Rs m12745 1.6%   
Profit before tax Rs m2173,990 0.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m720,098 0.0%   
Profit after tax Rs m1453,892 0.0%  
Gross profit margin %6.332.9 19.1%  
Effective tax rate %34.527.2 127.2%   
Net profit margin %2.521.8 11.6%  
BALANCE SHEET DATA
Current assets Rs m225198,235 0.1%   
Current liabilities Rs m173106,652 0.2%   
Net working cap to sales %9.437.0 25.5%  
Current ratio x1.31.9 70.1%  
Inventory Days Days7719 400.2%  
Debtors Days Days76652 1,484.8%  
Net fixed assets Rs m161135,778 0.1%   
Share capital Rs m101586 17.2%   
"Free" reserves Rs m36218,713 0.0%   
Net worth Rs m137219,299 0.1%   
Long term debt Rs m671,684 4.0%   
Total assets Rs m387334,013 0.1%  
Interest coverage x2.8100.3 2.8%   
Debt to equity ratio x0.50 6,387.1%  
Sales to assets ratio x1.40.7 193.7%   
Return on assets %6.716.4 40.7%  
Return on equity %10.224.6 41.7%  
Return on capital %16.233.8 48.0%  
Exports to sales %053.8 0.0%   
Imports to sales %016.4 0.0%   
Exports (fob) Rs mNA133,248 0.0%   
Imports (cif) Rs mNA40,615 0.0%   
Fx inflow Rs m0133,248 0.0%   
Fx outflow Rs m044,946 0.0%   
Net fx Rs m088,302 0.0%   
CASH FLOW
From Operations Rs m1833,289 0.1%  
From Investments Rs m-35,987 -0.1%  
From Financial Activity Rs m40-13,648 -0.3%  
Net Cashflow Rs m5525,831 0.2%  

Share Holding

Indian Promoters % 0.0 48.8 -  
Foreign collaborators % 34.2 3.1 1,113.7%  
Indian inst/Mut Fund % 0.1 38.3 0.1%  
FIIs % 0.0 20.8 -  
ADR/GDR % 0.0 0.0 -  
Free float % 65.8 48.2 136.6%  
Shareholders   42,673 338,639 12.6%  
Pledged promoter(s) holding % 0.0 14.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DECIPHER LABS With:   CIPLA    SUN PHARMA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    



Today's Market

4 Reasons Why Sensex Rallied 1,534 Points Today(0)

Bulls marked a strong comeback today as Indian share markets ended nearly 3% higher. After opening the day higher, equity markets extended gains as the session progressed and ended near the day's high.

Related Views on News

Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary (Views On News)

Jul 2, 2021

Here's why the company sold its business unit to Eugia Pharma Specialities.

Aurobindo Pharma's Stock Falls After Profits Decline 7% (Views On News)

Jun 1, 2021

Aurobindo Pharma shares fell nearly 4% after quarterly earnings disappoint.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

Nifty Pharma Index - Bulls are Losing the Ground (Views On News)

Mar 16, 2022

For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far...(Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022(Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022(Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look...(Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better?(Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DECIPHER LABS SHARE PRICE


May 20, 2022 (Close)

TRACK DECIPHER LABS

  • Track your investment in DECIPHER LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DECIPHER LABS - WANBURY COMPARISON

COMPARE DECIPHER LABS WITH

MARKET STATS